ZNTL Stock Cash Flow Statements

Zentalis Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Zentalis Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

operating activities:
consolidated net income	-26,874,000	-48,279,000		-40,158,000	-88,277,000	10,040,000		-55,540,000	-112,564,000	-63,262,000		-54,500,000	-68,392,000	-59,237,000		-10,492,000	-55,062,000	-50,444,000	-40,356,000	-34,665,000	-27,292,000	-16,235,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	160,000	262,000	317,000	321,000	327,000	324,000	337,000	348,000	344,000	360,000	359,000	375,000	348,000	344,000	209,000	137,000	119,000	79,000	33,000	51,000	38,000	38,000
fixed asset impairment	0	1,152,000
share-based compensation	6,286,000	6,486,000	31,363,000	10,362,000	12,711,000	12,833,000	13,880,000	13,867,000	13,342,000	13,733,000	9,612,000	10,317,000	16,764,000	10,147,000	8,471,000	7,656,000	9,919,000	9,691,000	7,887,000	7,249,000	7,681,000	329,000
gain on disposal of equipment
non-cash impact of license revenue				0	0	-25,560,000
non-cash recognized gain mark-to-market of equity securities	-4,640,000	7,023,000
accretion of discounts on marketable securities	-781,000	-1,034,000	-1,397,000	-1,645,000
deconsolidation of variable interest entity
changes in operating assets and liabilities:
contracts receivable	0	5,000,000
prepaid expenses and other assets	2,349,000	663,000	228,000	5,440,000	1,606,000	-1,056,000	-479,000	-1,277,000	-1,005,000	-2,917,000	-1,885,000	1,943,000	-2,509,000	-4,154,000	-815,000	5,633,000	-2,580,000	-1,357,000	265,000	-988,000	-3,746,000	-1,050,000
accounts payable and accrued liabilities	-10,584,000	-4,023,000	-2,562,000	-12,008,000	11,797,000	-15,249,000	10,397,000	6,327,000	-4,394,000	-1,411,000	5,050,000	6,452,000	4,599,000	-574,000	1,606,000	7,472,000	1,531,000	3,307,000	5,258,000	7,837,000	1,159,000	53,000
operating lease right-of-use assets and liabilities	-93,000	114,000	258,000	-690,000			350,000	-271,000	235,000	309,000	822,000	1,230,000	897,000	1,381,000	1,472,000	-392,000	-515,000	782,000	-498,000	-158,000	-4,000	-7,000
net cash from operating activities	-34,708,000	-32,636,000	-39,702,000	-44,045,000	-35,139,000	-51,974,000	-40,599,000	-38,665,000	-79,275,000	-49,283,000	-37,329,000	-33,199,000	-43,027,000	-50,196,000	-37,021,000	-33,490,000	-46,113,000	-37,469,000	-27,357,000	-20,564,000	-22,033,000	-16,871,000
capex	0	0	0	0	-181,000	-40,000	-173,000	-91,000	0	0	-160,000	-1,660,000	-278,000	-450,000	-2,191,000	-2,661,000	-819,000	-369,000	-661,000	-41,000	-25,000	-6,000
free cash flows	-34,708,000	-32,636,000	-39,702,000	-44,045,000	-35,320,000	-52,014,000	-40,772,000	-38,756,000	-79,275,000	-49,283,000	-37,489,000	-34,859,000	-43,305,000	-50,646,000	-39,212,000	-36,151,000	-46,932,000	-37,838,000	-28,018,000	-20,605,000	-22,058,000	-16,877,000
investing activities:
purchases of marketable securities	-40,186,000	-19,530,000		-59,236,000	-19,394,000	-10,115,000	-95,987,000	-264,110,000	-125,206,000	-63,879,000	-125,984,000	-129,601,000	-198,322,000	-79,254,000	-83,223,000	-202,473,000	-23,378,000	-54,434,000	-96,899,000	-166,849,000
proceeds from maturities of marketable securities	70,000,000	60,000,000		74,000,000	54,000,000	71,700,000	54,100,000	146,750,000	198,457,000	106,000,000	114,250,000	151,279,000	56,500,000	99,500,000	128,681,000	78,011,000	90,800,000	68,328,000	87,910,000
proceeds from sale of property and equipment	564,000	5,000	0	0
purchases of property and equipment			0	0	-181,000	-40,000	-173,000	-91,000			-160,000	-1,660,000	-278,000	-450,000	-2,191,000	-2,661,000	-819,000	-436,000	-661,000	-41,000	-25,000	-31,000
net cash from investing activities	30,378,000	40,475,000	32,283,000	48,243,000	34,490,000	61,545,000	-42,060,000	-117,451,000	72,932,000	42,121,000	-11,894,000	20,018,000	-142,100,000	19,796,000	43,267,000				-9,650,000	-137,890,000	-137,261,000	-31,000
financing activities:
proceeds from issuance of common stock under equity incentive plans	0	189,000	0	92,000	9,000	248,000	0	309,000	941,000	373,000	1,116,000	589,000	158,000	1,258,000	3,663,000
net-settlement of restricted stock unit vesting			0	0	0	-241,000
net cash from financing activities	0	189,000	0	92,000	9,000	7,000	0	309,000	236,621,000	373,000	49,741,000	589,000	209,455,000	1,258,000	12,267,000				-594,000	155,899,000	191,660,000	13,474,000
net increase in cash, cash equivalents and restricted cash	-4,330,000	8,028,000	-7,419,000	4,290,000	-640,000	9,578,000	-82,659,000	-155,807,000
cash, cash equivalents and restricted cash at beginning of period	0	36,528,000		0	0	30,719,000		0	0	45,696,000		0	0	62,584,000		0				0
cash, cash equivalents and restricted cash at end of period	-4,330,000	44,556,000		4,290,000	-640,000	40,297,000		-155,807,000	230,278,000	38,907,000		-12,592,000	24,328,000	33,442,000		-8,363,000				-2,555,000
loss on disposal of equipment			0	0	53,000	-66,000	410,000								0	0	0	15,000
net income
operating lease right-of-use asset and fixed asset impairment						772,000	0	0	0	4,953,000
noncash consideration portion of zentera in-process research and development							0	0
goodwill impairment
non-cash impact of revenues from licensing and sales of intellectual property
non-cash recognized mark-to-market of equity securities			2,692,000	-5,667,000	28,916,000	-31,169,000
loss on equity method investment							0	0	13,704,000	2,310,000	6,822,000	2,371,000	5,338,000	1,751,000
deferred income taxes							0	0	-756,000	-97,000
deconsolidation of kalyra			0	0	0	-79,000
accounts receivable															104,000	-103,000	243,000	169,000	-295,000	-49,000	66,000	1,000
purchases of marketable debt securities
proceeds from maturities of marketable debt securities
proceeds from sale of marketable equity securities
proceeds from issuance of common stock							0	0			48,625,000	0			9,750,000				-594,000
cash, cash equivalents and restricted cash at beginning of year																		56,271,000				67,489,000
cash, cash equivalents and restricted cash at end of year																		32,260,000				64,061,000
supplemental disclosure of cash flow information:
income taxes paid
supplemental disclosure of non-cash investing and financing activities:
right-of-use assets obtained in exchange for operating lease liabilities
proceeds from sale of marketable securities
(accretion of discounts)/amortization of premiums on marketable securities						-2,764,000	-4,555,000	-2,119,000	-3,222,000	-3,261,000
ipr&d impairment															0
recognized tax gain on ipr&d impairment															0
gain on deconsolidation of zentera, net of tax															0
deconsolidation of zentera cash															0
accrued capital expenditures										209,000			-135,000	226,000
(loss)/gain on disposal of equipment
net decrease in cash, cash equivalents and restricted cash										-6,789,000		-12,592,000
proceeds from issuance of common stock in initial public offering																			0	0
contributions from noncontrolling interest owners																			0	0
proceeds from the issuance of series c convertible preferred units																			0	0	0	14,228,000
amortization of premiums on marketable securities												-1,266,000	-129,000	146,000	196,000	191,000	232,000	289,000	332,000	159,000
deferred financing costs																						-754,000
accrued deferred financing costs
net increase/(decrease) in cash, cash equivalents and restricted cash														-29,142,000	18,513,000	-8,363,000
costs incurred in connection with initial public offering included in accounts payable and accrued expenses																					-1,860,000	1,930,000
net cash provided by/used in investing activities																	66,603,000	13,458,000
proceeds from exercise of stock options
net cash used in/provided by financing activities
decrease in cash, cash equivalents and restricted cash																		-24,011,000				-3,428,000
amounts accrued for purchases of property and equipment																		67,000				25,000
increase/(decrease) in cash, cash equivalents and restricted cash
costs incurred in connection with equity offering included in accounts payable and accrued liabilities

We provide you with 20 years of cash flow statements for Zentalis Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Zentalis Pharmaceuticals stock. Explore the full financial landscape of Zentalis Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Zentalis Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.